Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Pregnant women and their neonates are perhaps the last true therapeutic orphans. The majority of pregnant women take at least one medication to treat a maternal condition but very few pharmacokinetic, pharmacodynamic or clinical trials are currently conducted during pregnancy. As a consequence, evidence to guide effective drug treatment of pregnant women is largely lacking. Off-label use of drugs in neonates is a worldwide issue and of paramount concern. Neonatologists are primarily dependent on clinical experience and data extrapolation from adults, children, and infants to guide optimal drug choice, and to select the most safe and effective dosing regimen. Unfortunately, this has resulted in considerable differences in prescribing practices both between and within countries, for many frequently used drugs in neonates. There is a moral obligation to adopt pregnant women and their neonates into the mainstream of health care research and practice.
